• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Consumer Cyclical·KVUE
Held by 3 Gurus
Share

Kenvue Inc. Stocks

$ 19.31Last Updated 30.10.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 37.09B

$ 19.31
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.01%

Fund

Bridgewater Associates

Steven Cohen

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

Point72 Asset Management, L.P.

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.01%
Steven CohenPoint72 Asset Management, L.P.0.0%+0.00%

Latest news

21.01.2026 15:50

New York morning: Trump's rhetoric will set the tone for trading

03.11.2025 17:12

New consumer products giant: Kimberly-Clark buys Tylenol maker

23.09.2025 10:14

Highlights for the morning: Nvidia's megaproject, AI industry shortages and Tylenol issues

22.09.2025 10:19

Highlights for the morning: OpenAI and Luxshare vs. Apple, China kept betting, Tylenol dispute

11.09.2025 17:29

Morningstar's picks for the 10 best dividend stocks. How do you avoid the "yield trap"?

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of KVUE is 19.1 and suggests 0.984% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.11.2026 02:15

Chipmakers' stocks posted their biggest jump since July. The rally did not halt Nvidia's decline

10.11.2026 01:24

A $1 trillion debt boom threatens to trigger an “interest rate shock” in the data center sector — Bloomberg

10.11.2026 00:48

Oppenheimer recommended buying AMD stock. How is the scandal involving Nvidia's CEO affecting the stock?

09.11.2026 23:15

"A Worst-Case Scenario": Why the Risk of Nvidia's CEO Leaving Is Dangerous for the Entire AI Industry

09.11.2026 22:56

Hedge funds staged a near-record sell-off of tech stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026